Pharmaceutical Shipping: Regulations, Cold Chain, and Security

Pharmaceutical freight can involve strict requirements for handling, documentation, security, and temperature control. Prescription drugs, biologics, vaccines, and controlled substances can each present different transportation considerations, and the requirements that apply depend on the product and the role each party performs.

This article covers the regulatory frameworks that can apply to pharmaceutical distribution, how temperature-sensitive products are managed, the documentation and security practices shipments may require, and what shippers should evaluate when selecting a logistics provider.

Rules and Regulations for Shipping Pharmaceuticals

Pharmaceutical shipping in the United States can involve multiple federal and state requirements. Which requirements apply depends on the product, the activity being performed, and each party’s role in the supply chain.

FDA Current Good Manufacturing Practice (cGMP): CFR Title 21, Parts 210 and 211

FDA current good manufacturing practice regulations establish requirements for the manufacture, processing, packing, and holding of drugs. For finished pharmaceuticals, 21 CFR Part 211 also includes requirements for warehousing and distribution, including storing products under appropriate temperature, humidity, and light conditions and maintaining written distribution procedures.

The full regulations are available in the Code of Federal Regulations Title 21. The specific requirements that apply can depend on the product and the role an entity performs in the supply chain.

Good Distribution Practice (GDP)

Good Distribution Practice, or GDP, refers to quality principles for maintaining the integrity of pharmaceutical products during storage and distribution. Organizations such as the World Health Organization publish GDP guidance covering areas such as storage conditions, transportation, documentation, personnel, equipment, and quality systems.

GDP requirements also exist under European Union law for wholesale distribution of medicinal products, but those EU requirements are not part of the U.S. Code of Federal Regulations. In the United States, pharmaceutical distribution requirements instead come from applicable federal and state laws, product-specific requirements, and quality procedures.

Drug Supply Chain Security Act (DSCSA)

Passed in 2013, the Drug Supply Chain Security Act (DSCSA) created a federal framework for identifying and tracing certain prescription drugs as they move through the U.S. supply chain. Enhanced requirements call for secure, interoperable electronic exchange of product tracing information at the package level among manufacturers, repackagers, wholesale distributors, and dispensers subject to the law.

DSCSA also establishes requirements for authorized trading partners. Third-party logistics providers have a distinct role under the law because they can take possession of prescription drugs without taking ownership. Applicable 3PLs must meet licensing requirements and report licensure and other facility information to FDA annually.

Implementation has occurred in phases, and some exemptions remain in effect. As of 2026, FDA has extended certain section 582 exemptions for qualifying small dispensers, and where applicable their trading partners, through November 27, 2027.

Who Bears Responsibility

Regulatory responsibility in pharmaceutical distribution depends on the product, the activity being performed, and each party’s role in the supply chain. Manufacturers, repackagers, wholesale distributors, dispensers, and applicable third-party logistics providers can each have different obligations under federal and state law.

For example, manufacturers and other covered trading partners may have product-tracing and verification responsibilities under the DSCSA, while applicable 3PLs have separate licensing and authorized trading partner requirements. Transportation providers may also be responsible for following shipment-specific handling, security, documentation, and temperature requirements established for the freight.

Clear handoffs matter because compliance depends on each party understanding which requirements apply to its role and which shipment information needs to move with the product.

Four Core Requirements for Pharmaceutical Shipping

Pharmaceutical shipping requirements vary by product, but transportation planning commonly needs to address four areas: temperature conditions, cleanliness, physical protection, and documentation. The specific controls required for each shipment should be based on the product’s labeled storage and handling conditions, applicable regulations, and the shipper’s quality procedures.

Temperature Control

Temperature requirements should be established before a pharmaceutical shipment moves. FDA-approved labeling can include specific storage and handling conditions, and those conditions are supported by stability data used to demonstrate that the drug will maintain its strength, quality, and purity through its shelf life.

Depending on the product, shipping conditions may include:

• Refrigerated: commonly within a defined refrigerated range, such as 2–8°C.
• Controlled room temperature: products may be labeled for room-temperature storage with defined allowable conditions or excursions.
• Frozen: some products require storage and transportation below freezing.
• Ultra-low or cryogenic: certain specialized products require temperatures well below standard frozen conditions.

These categories are useful for transportation planning, but the required range should always come from the specific product’s labeled storage conditions rather than a general pharmaceutical classification.

For temperature-sensitive freight, the transportation plan should also establish the appropriate equipment, packaging, monitoring method, and response process before pickup. If an excursion occurs, the product should be evaluated against its labeled storage conditions and applicable quality procedures before a disposition decision is made.

Cleanliness

Pharmaceutical freight should be transported and stored in conditions that protect the product from contamination, moisture, pests, residue, and other environmental risks. The appropriate cleanliness and inspection procedures depend on the product, packaging, equipment, and shipper requirements.

Before loading, transportation equipment should be checked to confirm that it is suitable for the shipment and free from conditions that could affect product quality. When cleaning or inspection procedures are required by the shipper or an applicable quality program, those steps should be completed and documented before the freight moves.

Protection

Pharmaceutical freight should be protected from damage, tampering, unauthorized access, and theft throughout transportation and handling. The level of protection needed depends on the product’s value, theft risk, packaging, regulatory requirements, and shipper protocols.

Depending on the shipment, controls may include tamper-evident packaging, trailer seals and locks, GPS tracking, restricted shipment information, driver verification, secure parking, and documented handoffs. Higher-risk products, including certain controlled substances and high-value pharmaceuticals, may require additional security measures based on the requirements established for the shipment.

Documentation

Documentation requirements depend on the product, the parties involved, and the requirements that apply to the shipment. Records should be sufficient to show how required transportation and handling conditions were maintained and to support investigation of any exception that occurs.

Depending on the shipment, documentation may include temperature-monitoring data, equipment or facility inspection records, cleaning records, seal information, documented handoffs, and records of any excursion or other exception. DSCSA product-tracing information may also be required when the shipment involves a covered transaction.

For wholesale prescription drug distributors, 21 CFR 205.50 establishes specific storage, handling, security, and recordkeeping requirements. Those requirements apply to wholesale drug distributors within that regulatory framework and should not be treated as universal requirements for every carrier or 3PL.

Maintaining Cold Chain Integrity from Start to Finish

Cold chain integrity means maintaining the temperature conditions required for a product throughout storage, handling, and transportation. For temperature-sensitive pharmaceuticals, even a relatively short excursion can require evaluation before the product can continue through the supply chain.

Where Cold Chains Break

Temperature risk can increase at transition points such as loading, unloading, vehicle transfers, warehouse staging, and final delivery. A refrigerated vehicle may maintain the required range during transit, for example, while the product is still exposed to risk if it remains too long in an uncontrolled staging area.

Other potential failure points include equipment malfunctions, inadequate packaging for the expected transit conditions, improper pre-conditioning, delayed transfers, and handling that does not follow the product’s defined temperature requirements.

Temperature Monitoring

For temperature-sensitive pharmaceuticals, monitoring should be matched to the product’s labeled storage conditions and the transportation plan. Depending on the product and shipment, monitoring may involve data loggers, vehicle sensors, packaging monitors, or systems that provide real-time temperature information.

Monitoring records should provide enough information to determine whether the product remained within its defined conditions during transportation and to support evaluation if an excursion occurs. Monitoring devices should also be appropriate for the required temperature range and maintained and calibrated according to applicable procedures.

Real-time alerts can help transportation teams identify and respond to developing temperature issues, but continuous remote monitoring is not a universal requirement for every pharmaceutical shipment.

WHO guidance emphasizes maintaining and monitoring the storage and transportation conditions specified for pharmaceutical products, with controls based on the product’s requirements.

Excursion Response Protocols

When a temperature excursion occurs, it should be documented and escalated promptly according to the procedures established for the product and shipment. The affected product may need to be held or quarantined while the excursion is evaluated against its labeled storage conditions, stability information, and applicable quality procedures.

Written response procedures should define who needs to be notified, what information should be recorded, how the product will be evaluated, and who is authorized to make the disposition decision. Depending on the circumstances, the product may be released, further evaluated, returned, or rejected.

Having those procedures established before pickup helps ensure that transportation teams know how to respond if conditions fall outside the defined range.

Warehousing and Storage

Storage conditions for pharmaceutical products should match the requirements established for the product. Depending on the product, that may include controls for temperature, humidity, light, security, and other environmental conditions.

For temperature-sensitive products, storage areas and monitoring systems should be appropriate for the required range, with procedures in place for equipment failures, power outages, alarms, and other events that could affect product conditions. WHO guidance also emphasizes maintaining storage conditions specified on the product label or by the manufacturer.

When pharmaceutical freight will move through third-party warehousing, shippers should confirm that the facility can support the product’s storage requirements and the documentation, monitoring, security, and handling procedures required for the shipment. For a broader overview of how temperature-controlled logistics works across product categories, see our dedicated article.

Documentation Requirements for Pharmaceutical Shipments

Documentation in pharmaceutical logistics supports regulatory compliance and provides the records needed to investigate shipment exceptions. The specific records required and how long they must be retained depend on the product, activity, and applicable requirements.

Transaction Documentation Under DSCSA

Under the enhanced DSCSA framework, manufacturers, repackagers, wholesale distributors, and dispensers subject to the product-tracing requirements must exchange Transaction Information (TI) and Transaction Statements (TS) electronically and in a secure, interoperable manner. Transaction Information includes identifying details about the product and transaction, including package-level product identifiers.

Those covered trading partners must also maintain systems and processes that can promptly gather the information needed to produce transaction information for each applicable transaction back to the manufacturer in the event of a recall or certain investigations. Records subject to DSCSA retention requirements generally must be maintained for at least six years.

Transaction History (TH) is no longer exchanged as a separate tracing document under the enhanced requirements that took effect November 27, 2023. Instead, the system is designed to allow the necessary transaction information to be gathered electronically through the supply chain.

Temperature and Condition Records

For shipments that require temperature monitoring, records should provide enough information to determine whether the product remained within its defined conditions during transportation.

Depending on the monitoring method and shipment requirements, records may include the device or sensor ID, calibration information, timestamped temperature data, alerts, and any actions taken in response to an exception.

If a temperature excursion occurs, the monitoring record should be preserved with the other shipment documentation needed to evaluate the event and support the resulting disposition decision.

Vehicle and Facility Inspection Records

When transportation equipment or storage areas are subject to inspection requirements, records should document that they were suitable for the product and shipment before use.

Depending on the applicable procedures, those records may include the date of inspection, equipment or facility condition, cleanliness, temperature status when relevant, any corrective actions taken, and the person completing the inspection.

Inspection records can help demonstrate that required handling conditions were checked and can provide supporting documentation if a quality issue or shipment exception needs to be investigated.

Chain of Custody Documentation

Chain-of-custody documentation can help establish who had possession of a pharmaceutical shipment at key points in transit and provide a record for investigating loss, damage, tampering, or other exceptions.

Depending on the product and shipment requirements, documentation may include pickup and delivery records, seal numbers, transfer or handoff records, driver and vehicle information, and records of condition when custody changes.

Controlled substances can involve additional DEA requirements, but common and contract carriers are generally exempt from DEA registration when possession occurs in the usual course of their business. DEA reporting obligations for theft or significant loss generally fall on the applicable DEA registrant rather than automatically on the carrier.

Personnel Training Records

Personnel involved in pharmaceutical storage, handling, or transportation should receive training appropriate to their responsibilities and the requirements of the products they handle.

Depending on the role and applicable procedures, training may cover temperature-sensitive handling, security, documentation, contamination prevention, excursion response, and shipment-specific requirements.

When training records are required, they should provide sufficient documentation to show that personnel have completed the training applicable to their responsibilities and support review during audits or investigations.

Shielding Pharmaceutical Shipments from Theft

Pharmaceutical shipments can present significant theft risk because some products are high-value, regulated, difficult to replace, or attractive for illicit resale. The level of risk varies by product, lane, shipment value, and handling requirements.

Security planning should address the shipment throughout transportation and any storage or transfer points. Depending on the risk involved, that can include controls for the vehicle, facility access, route information, personnel verification, parking, and incident response.

Vehicle Security

Vehicle security should be matched to the value, theft risk, regulatory requirements, and shipper protocols for the load. Depending on the shipment, controls may include trailer seals, locks, GPS tracking, route monitoring, stop restrictions, and procedures for responding to unexpected delays or route deviations.

For higher-risk pharmaceutical shipments, shippers may also require additional measures such as team drivers, restricted parking locations, enhanced tracking, or other shipment-specific security controls. Seal numbers and other security information should be documented when those controls are part of the transportation plan.

Facility Security

Facility security should be based on the value, theft risk, regulatory requirements, and handling needs of the products stored or transferred there. Depending on the operation, controls may include restricted access to pharmaceutical storage areas, visitor or personnel logs, monitored loading docks, secured trailer parking, alarms, and camera coverage.

For higher-risk shipments, additional controls may be appropriate, such as limiting access to designated personnel, documenting trailer and seal status, using physical trailer restraints, or applying other site-specific security procedures.

For a broader look at cargo security, see How to Protect Your Supply Chain From Cargo Theft.

Driver and Personnel Verification

Driver and personnel verification should support the identity, access, and security requirements established for the shipment. Depending on the load, that may include verifying the driver at pickup and delivery, confirming tractor and trailer information, providing receiving facilities with expected arrival details, and limiting shipment information to personnel who need it.

For higher-risk pharmaceutical shipments, shippers or facilities may require additional personnel controls, such as background screening, restricted access, or enhanced identity verification. Those requirements should be based on the product, security plan, facility procedures, and contractual requirements.

Controlled-substance shipments can involve additional DEA requirements, but there is no general DEA-authorized carrier credential that every carrier must hold simply to transport controlled substances in the usual course of business.

Route Planning and Stop Minimization

Route planning can help reduce theft exposure by limiting unnecessary stops and time spent in unsecured locations. For higher-risk pharmaceutical shipments, fueling, rest, and overnight stops may be planned in advance, with secure parking locations used when practical and consistent with driver safety and operating requirements.

Route and schedule information should be limited to personnel who need it. When route monitoring is part of the shipment’s security plan, unexpected stops or significant deviations should be reviewed and documented according to established procedures.

Incident Response

Carriers and logistics providers should have procedures for responding to theft, attempted theft, suspected diversion, or other security incidents. Those procedures should address who needs to be notified, what information should be preserved, and how the shipment will be secured while the incident is investigated.

For controlled substances, DEA registrants must notify DEA in writing within one business day after discovering a theft or significant loss and are also responsible for submitting DEA Form 106 electronically within 45 days of discovery. For in-transit losses involving a supplier’s agent or a common contract carrier selected by the supplier, DEA states that the supplier is responsible for the required reporting.

For other pharmaceutical shipments, notification and reporting procedures should follow the shipper’s requirements, applicable regulations, contractual obligations, and established security procedures.

What to Look for in a Pharmaceutical Logistics Partner

Not every carrier or 3PL is set up to support every type of pharmaceutical freight. The requirements can vary significantly by product, lane, temperature conditions, security needs, and the regulatory role each party performs.

Before selecting a provider, shippers should confirm that its capabilities, procedures, equipment, and documentation align with the requirements of the specific freight being moved.

Temperature Control Capabilities

For temperature-sensitive products, confirm that the logistics provider can support the required temperature range and monitoring plan. Depending on the shipment, that may include appropriate equipment or packaging, calibrated monitoring devices, temperature records, and procedures for responding to excursions.

Shippers should also confirm what documentation the provider can supply to demonstrate that required conditions were maintained during transportation.

Quality Management and Written Procedures

Shippers should confirm that a prospective logistics partner has documented procedures appropriate to the pharmaceutical freight it will handle. Depending on the shipment and the provider’s role, those procedures may address temperature control, cleanliness, security, personnel training, excursion response, and recordkeeping.

For higher-risk or more tightly controlled products, a formal quality management system may also be appropriate. The key is whether the provider can demonstrate that required procedures are documented, followed, and available for review when needed.

DSCSA Compliance Infrastructure

For activities subject to the DSCSA, shippers should confirm which role the logistics provider performs and which requirements apply to that role. Third-party logistics providers have distinct requirements because they may take possession of prescription drugs without taking ownership.

Applicable 3PLs must be appropriately licensed and report licensure and other facility information to FDA annually to qualify as authorized trading partners. Shippers can check applicable state licensure and FDA’s annual reporting database as part of verifying a 3PL’s authorization status. FDA notes that inclusion in its reporting database does not, by itself, establish that a facility is properly licensed or in compliance with applicable requirements.

Controlled Substance Requirements

When a shipment contains controlled substances, shippers should confirm which DEA requirements apply to each party’s role. Common and contract carriers are generally exempt from DEA registration when they possess controlled substances in the usual course of their transportation business.

If a logistics provider performs activities beyond transportation that require DEA registration, the shipper should verify that the appropriate registration is in place. Shipment procedures should also address applicable security, documentation, custody, and theft or significant-loss reporting responsibilities.

Security Infrastructure and Protocols

Shippers should ask prospective logistics providers how they manage security for the specific freight involved. Depending on the product’s value, theft risk, shipper requirements, and route, relevant controls may include driver verification, trailer seals and locks, GPS or route monitoring, secure parking, restricted shipment information, facility access controls, and documented incident-response procedures.

For higher-risk shipments, additional measures such as enhanced tracking, team drivers, or other shipment-specific controls may be appropriate. The key is whether the provider can explain which security measures will apply to the shipment and how those procedures are implemented.

Pharmaceutical-Specific Experience

Experience with pharmaceutical freight can help demonstrate that a provider understands the handling, documentation, communication, and exception-management requirements these shipments may involve.

Shippers should ask about experience with freight similar to their own, including the product type, temperature requirements, security needs, lane, and any applicable regulatory considerations. References, supporting documentation, and willingness to participate in shipper review or audit processes can also help evaluate whether the provider is a good fit.

First Call Logistics supports temperature-sensitive, high-value, and regulated freight. For questions about whether our capabilities align with a specific pharmaceutical shipment, contact our team.

Getting Pharmaceutical Freight Right

Pharmaceutical freight requires the transportation plan to match the requirements of the product. Temperature conditions, documentation, security, handling procedures, and regulatory obligations can vary significantly by shipment and by the role each party performs.

The key is to establish those requirements before pickup and confirm which party is responsible for each part of the transportation plan. When an exception occurs, whether it involves temperature, timing, security, or documentation, clear procedures and communication help determine how the shipment should be handled next.

Pharmaceutical distribution requirements and technology continue to evolve. Shippers should verify the current requirements that apply to their products and confirm that transportation and logistics partners can support those requirements before freight moves.

For more detail on specific transportation needs, see our guides to refrigerated LTL, temperature-controlled freight, and hazmat shipping.

Frequently Asked Questions